van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512–27.
Article CAS PubMed PubMed Central Google Scholar
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608.
Article CAS PubMed PubMed Central Google Scholar
Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, et al. The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease. Alzheimers Dement. 2023;19:1227–33.
Article CAS PubMed Google Scholar
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.
Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 2022;79:975.
Article PubMed PubMed Central Google Scholar
Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381–7.
Article CAS PubMed PubMed Central Google Scholar
Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, et al. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011;70:657–61.
Article CAS PubMed PubMed Central Google Scholar
Xie L, Wisse LEM, Das SR, Vergnet N, Dong M, Ittyerah R, et al. Longitudinal atrophy in early Braak regions in preclinical Alzheimer’s disease. Hum Brain Mapp. 2020;41:4704–17.
Article PubMed PubMed Central Google Scholar
Costoya-Sánchez A, Moscoso A, Silva-Rodríguez J, Pontecorvo MJ, Devous MD, Aguiar P, et al. Increased medial temporal tau positron emission tomography uptake in the absence of amyloid-β positivity. JAMA Neurol. 2023.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292–323.
Folstein MF, Folstein SE, McHugh PR. Mini-mental state. J Psychiatr Res. 1975;12:189–98.
Article CAS PubMed Google Scholar
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412.2-2412-a.
Wechsler D. Wechsler memory scale-revised. New York: Psychological Corporation; 1987.
Bittner T, Zetterberg H, Teunissen CE, Ostlund RE, Militello M, Andreasson U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12:517–26.
Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14:1470–81.
Dumurgier J, Sabia S, Zetterberg H, Teunissen CE, Hanseeuw B, Orellana A, et al. A pragmatic, data-driven method to determine cutoffs for CSF biomarkers of Alzheimer disease based on validation against PET imaging. Neurology. 2022;99:e669–78.
Article CAS PubMed PubMed Central Google Scholar
Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685–91.
Article PubMed PubMed Central Google Scholar
Tustison NJ, Avants BB, Cook PA, Yuanjie Z, Egan A, Yushkevich PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29:1310–20.
Article PubMed PubMed Central Google Scholar
Manjón JV, Coupé P, Martí-Bonmatí L, Collins DL, Robles M. Adaptive non-local means denoising of MR images with spatially varying noise levels: spatially adaptive nonlocal denoising. J Magn Reson Imaging. 2010;31:192–203.
Modat M, Cash DM, Daga P, Winston GP, Duncan JS, Ourselin S. Global image registration using a symmetric block-matching approach. J Med Imaging (Bellingham). 2014;1:024003.
Ourselin S, Roche A, Subsol G, Pennec X, Ayache N. Reconstructing a 3D structure from serial histological sections. Image Vis Comput. 2001;19:25–31.
Avants BB, Yushkevich P, Pluta J, Minkoff D, Korczykowski M, Detre J, et al. The optimal template effect in hippocampus studies of diseased populations. Neuroimage. 2010;49:2457–66.
Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage. 2011;54:2033–44.
Rebsamen M, Rummel C, Reyes M, Wiest R, McKinley R. Direct cortical thickness estimation using deep learning-based anatomy segmentation and cortex parcellation. Hum Brain Mapp. 2020;41:4804–14.
Article PubMed PubMed Central Google Scholar
Das SR, Avants BB, Grossman M, Gee JC. Registration based cortical thickness measurement. Neuroimage. 2009;45:867–79.
Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.
Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 2017;13:205–16.
Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, Weiner MW, et al. Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection. Neuroimage. 2010;50:516–23.
Thyreau B, Sato K, Fukuda H, Taki Y. Segmentation of the hippocampus by transferring algorithmic knowledge for large cohort processing. Med Image Anal. 2018;43:214–28.
Leung KK, Ridgway GR, Ourselin S, Fox NC. Consistent multi-time-point brain atrophy estimation from the boundary shift integral. Neuroimage. 2012;59:3995–4005.
Lewis EB, Fox NC. Correction of differential intensity inhomogeneity in longitudinal MR images. Neuroimage. 2004;23:75–83.
Hobbs NZ, Henley SMD, Wild EJ, Leung KK, Frost C, Barker RA, et al. Automated quantification of caudate atrophy by local registration of serial MRI: Evaluation and application in Huntington’s disease. Neuroimage. 2009;47:1659–65.
Donohue MC, Sperling RA, Petersen R, Sun C-K, Weiner MW, Aisen PS, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317:2305–16.
Article CAS PubMed PubMed Central Google Scholar
Cleveland WS, Grosse E, Shyu WM. Local regression models. Statistical models in S. Wadsworth & Brooks/Cole; 1992. p. 309–76.
Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–23.
Beer JC, Tustison NJ, Cook PA, Davatzikos C, Sheline YI, Shinohara RT, et al. Longitudinal ComBat: a method for harmonizing longitudinal multi-scanner imaging data. Neuroimage. 2020;220:117129.
Bernal-Rusiel JL, Greve DN, Reuter M, Fischl B, Sabuncu MR, Alzheimer’s Disease Neuroimaging Initiative. Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage. 2013;66:249–60.
Thomas KR, Bangen KJ, Weigand AJ, Edmonds EC, Wong CG, Cooper S, et al. Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. Neurology. 2020;94:e397-406.
Article PubMed PubMed Central Google Scholar
Ye BS, Lee Y, Kwak K, Park Y-H, Ham JH, Lee JJ, et al. Posterior ventricular enlargement to differentiate dementia with lewy bodies from Alzheimer’s disease. J Alzheimers Dis. 2016;52:1237–43.
Article CAS PubMed Google Scholar
Khadhraoui E, Müller SJ, Hansen N, Riedel CH, Langer P, Timäeus C, et al. Manual and automated analysis of atrophy patte
留言 (0)